BioAtla

Update in progress

BCAB (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

BioAtla, Inc. is a clinical-stage biopharmaceutical company developing conditionally active biologic (CAB) antibody-based therapeutics for solid tumors. Lead programs include mecbotamab vedotin (BA3011) for undifferentiated pleomorphic sarcoma and NSCLC; ozuriftabmab vedotin (BA3021) for melanoma and head and neck squamous cell carcinoma; Evalstotug (BA3071), an anti-CTLA-4 CAB, for melanoma, RCC, colorectal cancer and NSCLC. The pipeline also includes BA3182 (bispecific), BA3361 (CAB-Nectin-4-ADC), and BA3142 (dual-CAB T-cell engager targeting B7-H3). Founded 2007, based in San Diego, CA.

Company score

Sentiment: -0.25; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.45; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.05; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.14; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.20; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive